Leucocytosis is a well-recognised haematological abnormality that develops in cancer patients. Although several mechanisms responsible for this morbidity can be speculated, recent studies have revealed that production of leucopoietic factors is the major cause of this paraneoplastic syndrome (Asano et al., 1977; Sata et al., 1979; Suda et al., 1980) . The leucopoietic factors are now called colony-stimulating factor (CSF), and there are at least four kinds of human CSFs: granulocyte (G) CSF, macrophage (M) CSF, granulocyte macrophage (GM) CSF and interleukin 3. All of these CSFs have been purified and their cDNAs molecularly cloned and sequenced (Kawasaki et al., 1985; Nagata et al., 1986; Wong et al., 1985; Yang et al., 1986) . These CSFs have been demonstrated in vitro to act on haematopoietic stem cells and progenitor cells at different stages of differentiation to stimulate self-renewal and differentiation of haematopoietic cells. Furthermore, the in vivo administration of recombinant CSF proteins revealed that these proteins are active in vivo and have a potent activity to increase the neutrophils (Antman et al., 1988; Cebon et al., 1988; Masaoka et al., 1989; Morstyn et al., 1989) .
In the present study, we attempted to characterise and identify factors with colony-stimulating activity produced by lung cancer cells to elucidate the involvement of CSFs in cancer-associated neutrophilia. Northern blot analysis and specific immunoassay revealed that constitutive production of multiple CSFs synergistically increased the neutrophil count in three patients with lung cancer.
Materials and methods
Cell culture Tumour tissues were obtained at surgical operation with informed consent. All three patients presented remarkable neutrophilia at least for 3 weeks, and antibiotic therapy did not decrease the neutrophil count. The clinical features of three patients with lung cancer associated with neutrophilia and two patients wihout neutrophilia used as negative controls are described in Table I Northern blot analysis Poly(A)+ RNA extraction, gel electrophoresis and Northern blot hybridisation were done by the methods reported previously (Suzuki et al., 1987 probe of 39 bases in length for detecting P-actin mRNA was also synthesised to examine the integrity and compare the applied amount of mRNA in each sample. The DNA sequence of the synthetic probes is given in Figure 1 . A 20 pmol aliquot of these synthetic probes was labelled at the 5' end with 40 pmol of [y-32P]ATP (5,000 Ci mmol ', Amersham International, UK) by T4 polynucleotide kinase (Boehringer Mannheim, Germany). The specific activities of the probes were about 2 x 106 c.p.m. pmol '. The poly(A)+ RNA from samples was electrophoresed on 1.2% formaldehyde-agarose gels and then transferred to nitrocellulose filters. Hybridisation was performed at 42°C for 24 h.
Immunoassay
The method for enzyme immunoassay (EIA) for G-CSF has been described previously (Motojima et al., 1989) . The EIA kit for GM-CSF was purchased from Genzyme (Boston, MA, USA). Radioimmunoassay (RIA) for M-CSF was developed using rabbit antiserum against recombinant human M-CSF (rhM-CSF). rhM-CSF was iodinated using lodo-gen by the method reported by Franker & Speck (1978) . For Colony-stimulating activity in tumour cell CM Colony-stimulating activity was detected in all CM from the three tumour tissues associated with neutrophilia, without concentration or dialysis. In contrast, CM from the tumour tissues from patients without neutrophilia did not stimulate colony formation (Table II) . Since non-adherent cells were used in this assay, colony-stimulating activity in CM was attributed to the activity of CSFs, but not to the activities that stimulate the adherent cells to produce the endogenous CSFs.
Northern blot analysis
The results of Northern blot analysis are shown in Figure 2 . G-CSF mRNA was detected in all three tumours associated used for detection of colony-stimulating factor and P-actin mRNA. G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor. with neutrophilia. The molecular size of G-CSF transcript was about 1.7 kb and appeared to be identical to that of con A-stimulated mononuclear cells. M-CSF mRNA was also detected in the three tumour cells. Two major bands, 4.2 kb and 3.8 kb, were observed in all tumour cells, but the intensity of the hybridisation band in patient 3 was faint. In contrast, no CSF gene transcript was detected in tumour cells from patients without neutrophilia. When the probe for Pactin was used, a hybridisation band with molecular size of 2.0 kb was observed in all samples with slight variation in intensity.
IR-G-CSF, IR-M-CSF and IR-GM-CSF in CM and plasma IR-G-CSF, M-CSF and GM-CSF were detected in all three
CM associated with neutrophilia except IR-GM-CSF in patient 3 (in whom GM-CSF mRNA was also faint). The IR-G-CSF and GM-CSF levels in plasma also increased in patients with neutrophilia. Since the colony-forming assay using authentic G-CSF and GM-CSF proteins showed that 50-100 pg ml' of each CSF protein was enough to stimulate the haematopoietic colony formation (data not shown), the concentration of IR-G-CSF and GM-CSF in plasma from patients with neutrophilia was high enough to stimulate the proliferation of the myeloid progenitor cells. In contrast, in patients without neutrophilia, IR-G-CSF and GM-CSF levels were below the detection limit in CM and plasma. IR-M-CSF was detected only in CM from the patients with neutrophilia. The plasma IR-M-CSF level in patients with neutrophilia was also higher than that in patients without neutrophilia, which remained in the normal range reported previously (Kimura et al., 1992) (Tables III  and IV) .
Discussion
The aetiology of leucocytosis in lung cancer patients may differ from patient to patient. It may be caused by concomitant infection, tumour necrosis, steroid administration or production of leucopoietic factors by tumour cells. Leucocytosis is a not uncommon paraneoplastic syndrome in lung cancer patients: in one retrospective study, Ascensao et al. <0.01 aRPMI-1640 medium plus 10% fetal bovine serum. CM, culture medium; IR, immunoreactive; G-CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
(1987) reported that 43 out of 105 patients with non-small cell lung cancer had leucocytosis, and in 13 of the 43 patients absolute neutrophilia was noted and the aetiology was attributed to the tumour itself. Although colony-stimulating activity was not examined in this study, neutrophilia caused by CSF production from tumour cells may not be rare in lung cancer patients.
In the present study, three patients with lung cancer developed remarkable leucocytosis, ranging from 31,400 to 44,100 fl-1, and 83-89% of leucocytes in the peripheral blood were mature neutrophils. Infection or chronic myelocytic leukaemia was ruled out by the laboratory examinations. The neutrophil count decreased to normal range after surgical resection of the tumour within 2-3 weeks in all cases. Furthermore, when the tumour recurred in patients 1 and 2, remarkable neutrophilia (25,000 and 19,00014l'1 respectively) was again observed. These clinical observations indicate that the neutrophilia of these patients was dependent on the presence of tumour cells.
In the tumours associated with neutrophilia, constitutive expression of G-, M-and GM-CSF genes was noted, and the corresponding CSF protein production was detected by specific immunoassays except GM-CSF protein in patient 3. The molecular size of each CSF transcript appears to be identical to that of con A-stimulated lymphocytes, indicating that gross rearrangement of CSF genes does not occur and that CSFs produced by tumour cells are probably identical to normal CSFs. This result is compatible with the fact that IR-CSFs in all cases are biologically active. It seems unlikely Table IV G-CSF, M-CSF and GM-CSF levels in plasma before and after surgery G-CSF (pg ml-') M-CSF (ng ml-') GM-CSF (pg ml-') (Wong et al., 1985; Yang et al., 1986; Rennick et al., 1987; Kaushansky et al., 1988) , there are few reports in which primary tumour cells constitutively produce multiple CSFs. Since the effect of CSF on the haematopoietic colony formation is synergistic in vitro (Metcalf, 1984) , it is reasonable to speculate that tumour-producing CSFs synergistically increase the neutrophil count in patients with tumours. The mechanism of constitutive production of CSF by tumour cells is not clear. However, there are no reports describing CSF gene rearrangement or gene amplification, and induction of trans-activating factors which enhance CSF gene transcription is now speculated. Recently, Miyatake et al. (1988) reported that a conserved DNA sequence was found in the promoter region of GM-CSF gene, and this sequence was involved in GM-CSF gene expression by p4Ox protein, which is a trans-activating DNA-binding protein produced by human T-cell leukaemia virus type I (HTLV-I)-infected cells. Interestingly, the same sequence (GAGRTTC-CAC) is also found in the promoter region of G-CSF and IL-3 (Tsuchiya et al., 1987) . These reports suggest the possibility that a common DNA-binding protein which happens to be produced in the lung cancer cells induces the simultaneous production of multiple CSFs.
The biological significance of tumour-producing CSFs has not been fully elucidated. There are reports demonstrating that CSF receptors are expressed in non-haematological tumours and that CSF enhances the growth and metastasis of the tumours (Horiguchi et al., 1988; Baldwin et al., 1989; Berdel et al., 1989) . Furthermore, it is suggested that neutrophils increased by tumour-producing CSF facilitate tumour growth and metastasis directly (Milas et al., 1984; Aeed et al., 1988; Welch et al., 1989) or indirectly by suppressing cellular immunity through induction of suppressor macrophages (Tsuchiya et al., 1988) or through suppression of killer cell induction (Seaman et al., 1982; Shau & Kim, 1988; Shau & Golub, 1989) . Indeed, two reports demonstrate that G-CSF treatment reduces the antitumour effect of interferon in vivo (Quesada et al., 1983; Segawa et al., 1991) . Therefore both CSF itself and neutrophils increased by CSF may exert an adverse effect on the clinical course of the patients with CSF-producing tumours. Further study will be needed to elucidate the biological significance of tumour-producing CSF on the clinical course of the patients.
